Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

Journal of Clinical Oncology
07 Aug, 2020 ,

Frank Bridoux et.al. conducted a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy and acute kidney injury without need for dialysis. The researchers concluded that adding cyclophosphamide did not sufficiently improve the efficacy-toxicity balance.